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Transcriptional induction of the 
heat shock protein B8 mediates 
the clearance of misfolded proteins 
responsible for motor neuron 
diseases
Valeria Crippa1,*, Vito G. D’Agostino2,*, Riccardo Cristofani3, Paola Rusmini3, Maria E. Cicardi3, 
Elio Messi3, Rosa Loffredo2, Michael Pancher2, Margherita Piccolella3, Mariarita Galbiati3, 
Marco Meroni3, Cristina Cereda1, Serena Carra4, Alessandro Provenzani2,† & Angelo Poletti3,5,†
Neurodegenerative diseases (NDs) are often associated with the presence of misfolded protein 
inclusions. The chaperone HSPB8 is upregulated in mice, the human brain and muscle structures 
affected during NDs progression. HSPB8 exerts a potent pro-degradative activity on several misfolded 
proteins responsible for familial NDs forms. Here, we demonstrated that HSPB8 also counteracts 
accumulation of aberrantly localized misfolded forms of TDP-43 and its 25 KDa fragment involved 
in most sporadic cases of Amyotrophic Lateral Sclerosis (sALS) and of Fronto Lateral Temporal 
Dementia (FLTD). HSPB8 acts with BAG3 and the HSP70/HSC70-CHIP complex enhancing the 
autophagic removal of misfolded proteins. We performed a high-through put screening (HTS) to find 
small molecules capable of inducing HSPB8 in neurons for therapeutic purposes. We identified two 
compounds, colchicine and doxorubicin, that robustly up-regulated HSPB8 expression. Both colchicine 
and doxorubicin increased the expression of the master regulator of autophagy TFEB, the autophagy 
linker p62/SQSTM1 and the autophagosome component LC3. In line, both drugs counteracted 
the accumulation of TDP-43 and TDP-25 misfolded species responsible for motoneuronal death in 
sALS. Thus, analogs of colchicine and doxorubicin able to induce HSPB8 and with better safety and 
tolerability may result beneficial in NDs models.
Different human diseases have been associated with an insufficient or an excessive intracellular response to pro-
teotoxic stress. Proteins that lose the capability to acquire and/or to maintain the proper folding, after genetic 
mutations or damages in their structures (e.g.: specific amino acids modifications due to free radical exposure, 
etc.), become aberrantly folded or misfolded and can trigger a proteotoxic stress1,2. Misfolded proteins may oli-
gomerize into aggregates that accumulate in cells. Misfolded proteins are potentially toxic by affecting several fun-
damental intracellular functions, either/both in their monomeric or/and in their aggregated forms, particularly 
in post-mitotic cells like neurons3,4. For these reasons, misfolded proteins are physiologically cleared from the 
cells by the protein quality control (PQC) system. The PQC system is composed of two main arms: the molecular 
chaperone, mainly represented by the heat shock proteins (HSPs)5–7 and the degradative pathways, including the 
proteasome, the autophagic response and the unfolded protein response (UPR)8,9. A specific degradative pathway 
for a given misfolded protein is selected by defined class of chaperones, with the assistance of co-chaperones5. 
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These may determine whether a misfolded protein has to be refolded or degraded. We found that a specific chap-
erone, the small heat shock protein B8 (HSPB8), recognizes and promotes the removal of the misfolded proteins 
associated with motoneuron diseases (MNDs) (i.e. mutant SOD1 and a TDP-43 fragment in Amyotrophic Lateral 
Sclerosis (ALS); androgen receptor with an expanded polyglutamine tract (ARpolyQ) in Spinal and Bulbar 
Muscular Atrophy (SBMA)) promoting their autophagic removal from motoneurons10–14. HSPB8 acts in conjunc-
tion with the co-chaperone BAG3 (by complexing with a 2:1 ratio)15–17, a protein capable to interact with HSP70 
bound to the ubiquitinating enzyme CHIP. After substrate ubiquitination, the autophagy receptor p62/SQSTM1 
recognizes the cargo and mediates its insertion into the autophagosomes13,14,18. Our data showed that HSPB8 is 
a limiting factor in this process, since its overexpression enhances while its silencing reduces the intracellular 
clearance of all MNDs-associated misfolded proteins tested so far9,12,13,19. It must be noted that HSPB8 is highly 
expressed in the anterior horn lumbar spinal cord motoneurons that survive at end stage of disease in transgenic 
(tg) ALS-SOD1 mice, where it possibly acts as a protective agent against mutant SOD1 neurotoxicity13,14. Similar 
data have been reported in autopsy specimens of spinal cord of ALS patients20. Notably, in mouse spinal cord, the 
HSPB8 expression levels decline with age13, indicating that motoneurons may become more vulnerable to mis-
folded protein toxicity during aging, as a result of low levels of this pro-autophagic protein.
HSPB8 is robustly induced also in muscles of both tg ALS-SOD1 mice1,19,21 and knock-in (KI) AR113Q mice 
(KI SBMA mice, a model of SBMA)9,22. Muscle tissues have been found to be the target of misfolded protein 
toxicity both in ALS and SBMA23–38. In ALS and SBMA mice models, HSPB8 induction in muscle is accom-
panied by the induction of several other genes involved in the autophagic clearance of misfolded proteins, like 
p62/SQSTM1, LC3, BAG3 and BAG11,21,22. HSPB8 also participates in the clearance of other misfolded proteins 
responsible for neurodegenerative diseases (NDs), such as two polyglutamine-containing proteins: mutant 
huntingtin responsible for Huntington Disease (HD) and ataxin-3 responsible for Spinal Cerebellar Ataxia 3 
(SCA-3)10, as well as of beta-amyloid involved in Alzheimer’s disease (AD)39 and of alpha-synuclein involved in 
Parkinson’s disease (PD)40,41. In addition, HSPB8 has been found mutated in two NDs, Charcot-Marie-Tooth type 
2 L disease and hereditary distal motor neuropathy type II (dHMNII)42,43. HSPB8 mutants lack their chaperone 
activity and impair lysosomal delivery of autophagosomes causing autophagic flux blockage41,44.
Collectively, these data prove that HSPB8 has a crucial activity for motor neuron (and possibly for muscle) 
function and viability and exerts a protective role against misfolded protein accumulation.
Based on these observations, in this study, we set up a high throughput screening (HTS) to identify com-
mercially available FDA-approved small molecules and selected natural compounds capable to enhance HSPB8 
expression in neuronal cells. The system takes advantage of the promoter region of the human HSPB8 gene fused 
to firefly luciferase. We found several compounds that activates the HSPB8 promoter and two of these, colchi-
cine and doxorubicin, were able to induce HSPB8 mRNA (and protein) expression. Interestingly, colchicine and 
doxorubicin also upregulated other proteins involved in the autophagic clearance of misfolded proteins such as 
the master regulator Transcription Factor EB (TFEB). The same two compounds were also able to greatly reduce 
the accumulation of misfolded species of TDP-43 and its 25 KDa fragment, whose accumulation is involved in 
sporadic forms of ALS (sALS).
Results
HSPB8 counteracts TDP-43 and TDP-25 misfolded species accumulation. The pro-degradative 
effects of HSPB8 have been proved to be efficient on different elongated polyQ containing proteins9,10,45 and on 
mutant proteins causing familial ALS forms (mutant G93A-SOD1 and a N-terminal fragment of TDP-43)13,14. We 
thus wanted to verify whether the protective activities of HSPB8 is not restricted to inherited NDs, but can also 
be extended to sporadic forms at least in the case of MNDs in which misfolded protein toxicity has been clearly 
implicated. To this purpose, we evaluated whether HSPB8 enhances the clearance of TDP-43 and its C-terminal 
fragment of 25 KDa (TDP-25), which is highly aggregation-prone due to the presence of a prion-like domain46. 
In fact, TDP-25 acts as seeding protein that sequesters into cytoplasmic insoluble aggregates endogenous wild-
type TDP-4347, thereby affecting its subcellular localization and function and causing toxicity in ALS cell models. 
The TDP-25 fragment (TDP-25, residues 184–414) is aberrantly generated by caspase cleavage of TDP-43, possibly 
under stress condition46. The cleavage removes one of the two RNA Recognition Motifs (RRM) of TDP-43 and 
the Nuclear Localization Sequence (NLS), retaining the Nuclear Exportation Sequence (NES) and thus allowing 
TDP-25 mislocalization to the cytoplasm, a process that has been proposed to be part of the disease mechanism 
in sALS46,47. TDP-25 is mainly degraded via autophagy, while the TDP-43 is mainly cleared by the proteasome and 
chaperone-mediated autophagy (CMA) (even if also macroautophagy could be involved). Thus, we initially analysed 
the differential effect of HSPB8 on the two TDP-43 protein variants. As shown in Fig. 1A, the overexpression of the 
two proteins correlated with the formation of p62 bodies in immortalized motoneuronal cells, a clear index of auto-
phagic flux blockage. In the case of TDP-43 the vast majority of the protein was found in the nuclei, while p62 bodies 
were localized in the cytoplasm. Therefore their appearance is an index of an overall induction of proteotoxic stress 
to the cells. In the case of TDP-25, the p62 bodies were adjacent to the TDP aggregates, but they did not physically 
sequester p62/SQSTM1. In both cases LC3, appeared with a diffuse distribution with some puncta indicative of the 
presence of autophagosomes (Fig. 1B). Thus, as expected, the autophagic clearance of the TDP-25 was impaired, 
allowing its accumulation into intracellular inclusions. The overexpression of HSPB8 promoted the clearance of the 
TDP-43 protein variants (Fig. 1C). In fact, the chaperone reduced the concentration of TDP-43 in the nucleus and 
its overexpression resulted in a robust reduction of intracellular TDP-25 aggregates from the cytoplasm. The HSPB8 
prodegradative activity was abolished by the autophagy inhibitor, 3-MA (Fig. 1C). The data obtained in immuno-
fluorescence microscopy, were also confirmed in filter retardation assay (FRA) and in Western Blot (WB) analysis 
(Fig. 1D), in which we showed that HSPB8 overexpression robustly reduced the overall accumulation of both TDP-
43 and TDP-25 insoluble species retained in cellulose acetate membrane (FRA and FRA quantification, Fig. 1D, left 
insets) and TDP-43 and TDP-25 soluble species detected in WB (WB, Fig. 1D, right insets).
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Development of the cellular system for the HTS of HSPB8 inducers. According to these and 
reported data10–13, we set up an assay that could reveal the up-regulation of HSPB8 mRNA expression in neu-
ronal cells, and that was amenable to high-throughput screening (HTS). The aim was to identify an inducer of 
HSPB8 expression after screening a library of small molecules. To this purpose, we amplified the human genomic 
DNA region upstream of the transcription initiation site of the human HSPB8 gene. This region was cloned 
into a luciferase-based expression vector to drive luciferase expression under the regulation of the exogenous 
HSPB8 promoter. The vector also contained a cDNA sequence coding for the GFP under the control of the 
CMV promoter to facilitate the screening of positive stably transfected clones. Initially, in transiently transfected 
immortalized motoneuronal (NSC34) cells, we tested whether the human HSPB8 promoter was activated by pro-
teasome inhibition, which we already proved to activate transcription of HSPB8 promoter and to induce HSPB8 
expression in different models11–13. The treatment with MG132, a potent inhibitor of the chymotryptic activity of 
the proteasome48,49, significantly induced the transcriptional activity of the human HSPB8 promoter in NSC34 
cells transiently transfected cells (Fig. 2A; + MG132 mean = 3.47 ± 0.24). We next transfected NSC34 cells and 
selected stably transfected clones (#Ns NSC34-GFP-hPromB8LUC cells) both for their resistance to Geneticin 
(G418) and for the GFP fluorescence. Positive clones have been characterized by the expression level of luciferase 
under basal condition (Fig. 2B). Clones #N3, #N4 and #N9, characterized by low to medium levels of luciferase 
expression were selected to obtain a larger signal to background window in the case of an increased expression 
of the luciferase protein during the screening process. These clones were further screened during HTS assay 
optimization to determine best cell density and signal to background ratio of luciferase activity. Although with a 
marginal improvement, the best condition of low background luciferase signal was obtained using #N4 clone cells 
at a density of 9*104 cells/well (Fig. 2C).
Figure 1. HSPB8 enhances the clearance of TDP-43 and TDP-25 (A,B) Immunofluorescence microscopy 
analysis (63x magnification and 2.5x zoom) of mouse motoneuronal NSC34 cells transiently overexpressing 
GFP-TDP-43 or GFP-TDP-25 plasmids. Cells were stained for the endogenous autophagic markers p62/
SQSTM1 (A) and LC3 (B). Nuclei were stained with DAPI. (C) Immunofluorescence analysis of NSC34 cells 
transiently overexpressing GFP-TDP-43 or GFP-TDP-25 and pCDNA3 or hHSPB8. Where indicated, cells 
were treated with 10 mM 3-methyladenine (3-MA) for the last 48 hrs prior to fixation. DAPI: nuclei staining. 
RED: human transfected HSPB8. (D) Representative Filter Retardation Assay (FRA) and FRA quantification 
(left insets), and Western Blot (WB; right insets) of the PBS extracts of NSC34 cells transiently overexpressing 
the GFP-TDP-43 or GFP-TDP-25 and pCDNA3 or hHSPB8 plasmids. The histogram represents densitometric 
analysis of three independent replicates for each sample (**p < 0.01 vs GFP-TDP-43; °°p < 0.01 vs GFP-
TDP-25).
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The quantification of the luciferase activity for the #N4 clone in basal condition or after treatment with MG132 
confirmed that the human HSPB8 promoter integrated into the genome of NSC34-GFP-hPromB8LUC cells was 
still able to respond to proteasome inhibition (Fig. 2D).
Hits identification and validation. We set up the HTS using MG132 as positive control with respect to 
untreated cells, used as negative control (Fig. 3A). In this workflow, the firefly luciferase signal was normalized 
with relative GFP fluorescence. The 5 μM MG132 treatment condition allowed to obtain a signal to background 
window of 3.4, a mean CV value among controls of 8.09% and a Z-factor of 0.63, indicating good parameters 
and reliability of the HTS assay (Fig. 3B). In Fig. 3C the distribution of green signal intensity is shown according 
to treatment of NSC34-GFP-hPromB8LUC [#N4] cells with the 2,000 compounds screened (list of compounds, 
Supplementary Table 1); the standard deviation of controls was as low as 1.82% (range from 102.5% to 98.86%). 
The plot of compounds (Fig. 3C), indicates that almost 56% of all molecules tested influenced GFP expression 
after 24 hrs treatment in these cells.
Therefore, to avoid nonspecific effect on luciferase expression, we normalized luminescence units with GFP 
fluorescence levels, and the results of primary screening were plotted according to progressive Z-score val-
ues (Fig. 3D). We classified compounds as activating (554, 27.7%), unaffecting, and interfering/inhibiting (48, 
Figure 2. Development of the cellular system for the screening of the HSPB8 promoter modulators 
(A) Validation of the GFP-hPromB8LUC plasmid. NSC34 cells were transiently transfected with GFP-
hPromB8LUC and pRL-TK plasmids. 24 hrs after transfection, cells were treated with DMSO or 10 μM MG132 
for the last 16 hrs prior to luminescence analysis. The histogram represents the Luminescence Counts Per 
Second (LCPS) of the inducible firefly luciferase normalized by the LCPS of renilla luciferase of six independent 
replicates (**p < 0.01 vs DMSO). (B) Clones selection of NSC34-GFP-hPromB8LUC (#Ns) stably transfected 
cells. Different #Ns clones were analysed for their luminescence levels, 48 hrs after plating. NSC34 untransfected 
cells were used as negative control. The histogram represents the firefly luciferase LCPS mean normalized by 
the total protein level mean of six independent replicates for each clone (**p < 0.01 vs NSC34 untransfected 
cells). (C) Optimization of cell number and signal to background ratio for HTS assay. Raw data of relative 
luminescence units detected by NSC34 clones after 24 hrs seeding at the indicated cell number. SD refers to two 
independent experiments. (D) Validation of the #N4 selected clone. NSC34-GFP-hPromB8LUC #N4 cells were 
analysed for their ability to respond to MG132 treatment. 24 hrs after plating, cells were treated with DMSO or 
10 μM MG132 for the last 16 hrs prior to luminescence analysis. The histogram represents the firefly inducible 
luciferase LCPS mean normalized by the total protein level mean of six independent replicates (**p < 0.01 vs 
DMSO).
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2.4%) (Fig. 3D and Supplementary Table 1). Within the activating compound’s set and among the first 246 
(12.3%) with a positive effect on luciferase expression, first 18 were confirmed in duplicate as top-ranked com-
pounds (Supplementary Table 2). By using the SODIAC chemistry ontology (http://ontochem.de/it-solutions/
what-we-offer/sodiac.html), we classified the top scored compound according to their recognized/noted bioac-
tivity and found categories prominently represented (in order of significance) by estrogen (9%), antineoplastic 
(9%), anti-inflammatory (12%), and antibacterial (12%) compounds (Fig. 3E).
Dose-response analysis of the 18 selected hits. The secondary screening has been performed as 
dose-response curve at 24 hrs in #N4 cells and by normalizing relative luminescence signals on absorbance data 
of the Alamar blue assay (Fig. 4A,B), to correct the cytotoxicity exerted by different compounds. MG132 was 
used as positive control. The cell viability resulted slightly affected by the majority of agents tested in the range of 
doses used, although cytotoxic effects of some compounds were prevalent at 10 μM, i.e. of thimerosal, doxoru-
bicin, and colchicine. As shown in Figs 4C,D and 5 out of 18 hits, represented by dexamethasone, flumethazone, 
colchicine, thimerosal, and doxorubicin displayed highly significant effect (P < 0.001) at 1 μM; 4 out of them, 
i.e. colistimetate, megestrol, melphalan, and metronidazole showed a significant effect (P < 0.05) at 1 μM; while 
cyproterone and nitrofurantoin compounds displayed a slight dose-response trend at the doses used, accounting 
for a total of 11 compounds (61%) globally validating approximately 0.5% of hits from the primary screening.
Validation of the hits for their ability to induce endogenous HSPB8 expression. We next deter-
mined whether the active compounds selected from our primary screening were also capable to induce the 
expression of the endogenous HSPB8 gene. In order to preserve the same promoter sequence adopted in the 
HTS assay and since NSC34 cells are of mouse origin, we used human derived neuroblastoma cells (SH-SY5Y), 
which are characterized by a neuronal-like phenotype and can be differentiated to neuronal cells with retinoic 
acid50. Cells were treated with the selected compounds for 24 hrs to test their effect on the total amount of HSPB8 
mRNA. The results have shown that only colchicine and doxorubicin were able to robustly upregulate the expres-
sion of the endogenous human HSPB8 in neuroblastoma cells (Fig. 5A). Induction was approximately of 3–5 
folds over control untreated cells. SH-SY5Y cells lack the estrogen receptors; in line, the estrogenic compounds 
identified in our primary screening were unable to induce HSPB8 in these cells.
Therefore, we focused on colchicine and doxorubicin as the best candidates to induce HSPB8 expression and 
protein production in neuronal cells. We initially performed a dose-response analysis to evaluate the optimal 
concentration required for colchicine and doxorubicin treatments to significantly induce HSPB8 expression. The 
results showed that colchicine was active at 100 nM (Fig. 5B,C), while doxorubicin was active at doses slightly 
higher of 500 nM (Fig. 5D,E). In both cases, a clear dose-response effect was observed both by measuring HSPB8 
mRNA level by Q-PCR (Fig. 5B,D) or the protein levels using a specific anti-human HSPB8 antibody by western 
blot (Fig. 5C,E).
Figure 3. Primary screening parameters and ranking of the 2,000 library compounds. (A) Distribution of 
positive (MG132) and negative (DMSO) controls according to firefly units normalized to GFP signal. #N4 cells 
were treated with 5 μM of MG132 or DMSO for 24 hrs in two columns (1–2 and 23-24, respectively) of each 
384-well plate ran (n = 25). (B) Parameters calculated from positive and negative controls validating robustness 
of the screening. (C) Distribution of GFP signals relative to each compound tested; values near to 100% indicate 
un-perturbing activity of compound on cellular or GFP-associated metabolism. (D) Plot of compounds ranked 
according to progressive Z score values (compounds are listed in Supplementary Table 2). (E) Chemical 
ontology (SODIAC) annotation according to the recognized bioactivity of HSPB8 activating compounds. 
*indicates less than 1% over-representation; NC = non classified.
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Colchicine and doxorubicin effects on the heat shock response. We next evaluated whether the two 
compounds modulated the heat shock response in neuronal SH-SY5Y cells by measuring the expression of the 
Heat Shock Factor 1 (HSF1) and of two classical nucleotide exchange factors (NEFs) assisting the ATP-dependent 
activities of HSP70 (and CHIP)9,13,15,21,51–53, BAG1 and BAG3. These NEFs control the alternative routing of 
HSP70/CHIP associated misfolded proteins to proteasome (BAG1) or autophagy (BAG3 in association with 
HSPB8); in particular, BAG3, which forms a stoichiometric complex with HSPB8, regulates the prodegrada-
tive action of HSPB813,15,21. While our cells positively responded to control stimuli by increasing two-fold HSF1 
expression during recovering time after heat shock (Fig. 6A,B), colchicine and doxorubicin were not able to 
change the basal expression level of HSF1 (Fig. 6A). Colchicine also did not modify BAG3 (Fig. 6C) or BAG1 
(Fig. 6E). Doxorubicin behaved similarly (Fig. 6D,F), but having a bi-phasic effect on BAG1. Taken together these 
data show that these drugs do not stimulate the HSF1-dependent stress response.
Colchicine and doxorubicin effects on the autophagic pathway. To better characterize the molec-
ular mechanisms of colchicine and doxorubicin in SH-SY5Y cells, we also tested the possibility that the two 
compounds may induce the up-regulation of genes involved in the autophagic clearance of misfolded proteins. 
Very interestingly, we found that both colchicine and doxorubicin were able to induce the expression of the auto-
phagy “master” gene regulator TFEB. The effect of colchicine was detectable only at 500 nM (Fig. 7A) while the 
induction of TFEB by doxorubicin was pronounced at the two higher doses utilized (Fig. 7B). Accordingly, the 
two compounds induced the expression of the autophagy markers p62/SQSTM1 and LC3 even if with different 
efficacies (Fig. 7C–F). To ascertain whether TFEB is the mediator of the induction of observed after colchicine 
and doxorubicin treatment, we evaluated the effects of the two compounds in cells in which TFEB was silenced 
with a specific siRNA. We obtained a 40% reduction of TFEB expression after siRNA-TFEB treatment; the lat-
ter was still efficient in reducing the upregulation of TFEB mRNA and protein upon exposure to colchicine or 
doxorubicin (Fig. 8A, compare scramble with siRNA-TFEB and 8B, silencing quantification). The induction of 
achieved with colchicine and doxorubicin was similar in control and TFEB-depleted cells (Fig. 8C), suggesting 
that TFEB is not the key factor responsible for the “de novo” synthesis of HSPB8 upon treatment with colchicine 
or doxorubicin. These data were also confirmed by WB analysis of TFEB and HSPB8 protein levels (Fig. 8D and 
quantification in Fig. 8E,F).
Colchicine and doxorubicin effects on TDP-43 and TDP-25 misfolded species accumula-
tion. Finally, we evaluated whether colchicine and doxorubicin were able to reduce the accumulation of TDP-
43 and its C-terminal fragment TDP-25 associated with sporadic forms of ALS. In SH-SY5Y transfected cells, 
fluorescence microscopy initially confirmed that both drugs increased the intracellular levels of endogenous 
HSPB8 (Fig. 9A). In addition, we found that very few GFP-TDP-43 expressing cells containing GFP-positive 
puncta were present (Fig. 9A, left panels). Conversely, in GFP-TDP-25 expressing cells we observed several cyto-
plasmic aggregates (Fig. 9A, right panels) that were almost completely removed by colchicine or doxorubicin 
Figure 4. Counterscreening of 18 hits by dose-response effects. (A,B) NSC34 #N4 cells were treated for 
24 hrs with four doses of indicated compounds. Relative cytotoxic activity was evaluated by Alamar blue assay 
following manufacture’s instruction. (C,D) Relative luminescence units detected in cells treated as in (A,B), 
normalized to cell viability (n = 2).
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treatments. Moreover, both colchicine and doxorubicin modified the overall levels of GFP-TDP-43 and of 
GFP-TDP-25 (Fig. 9A). In living SH-SY5Y cells, we carefully quantified the accumulation of GFP-TDP-43 and 
GFP-TDP-25 aggregates, here defined as “GFP-spots” (range of size from 1 to 10 μm2), using Operetta Imaging 
System, and Harmony software analysis (Fig. 9B,C). In GFP-TDP-43 transfected cells, only doxorubicin reduced 
the number of cells with “GFP-spots” (Fig. 9B); but, both drugs decreased the mean size of the spots (Fig. 9C). 
In cells expressing GFP-TDP-25, we found that both drugs were able to reduce the number of cells positive 
for “GFP-spots” (Fig. 8B) and to decrease the spots size (Fig. 9C). Next, we quantified the effects of the two 
Figure 5. Hits validation on endogenous HSPB8 expression in human neuronal cells (A) Q-PCR analysis 
of HSPB8 mRNA levels performed on SH-SY5Y cells. 24 hrs after plating, cells were treated for the last 24 hrs 
prior to extraction with 1 μM of different compounds or with DMSO (negative control) or 10 μM MG132 
(positive control). HSPB8 mRNA levels were normalized with RplP0 mRNA levels (relative levels); histogram 
represents the analysis of 4 independent replicates (**p < 0.01 vs DMSO). (B–E) Dose-dependent response 
analysis of colchicine (B,C) and doxorubicin (D,E) treatments performed on SH-SY5Y cells treated with 
100 nM, 500 nM or 1 μM of colchicine or doxorubicin, and with DMSO or 10 μM MG132 for 24 hrs. (B,D) 
Q-PCR analyses of HSPB8 mRNA levels. The histograms represent the HSPB8 mRNA relative levels mean of 4 
independent replicates (*p < 0.05 vs DMSO; **p < 0.01 vs DMSO). (C,E) WB and WB quantification of HSPB8 
protein levels. The histograms represent densitometric analysis of three independent replicates for each sample 
(*p < 0.05 vs DMSO; **p < 0.01 vs DMSO).
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Figure 6. Analysis of the heat shock response after colchicine and doxorubicin treatments (A–F) Q-PCR 
analyses of HSF1 (A,B), BAG3 (C,D) and BAG1 (E,F) mRNA levels performed on SH-SY5Y cells treated 
for the last 24 hrs prior to extraction with 100 nM, 500 nM or 1 μM of colchicine (A,C,E) or doxorubicin 
(B,D,F), and with DMSO or 10 μM MG132. Where indicated, cells where heat shocked for 1hr at 42 °C, and 
collected after the shock (no recovery) or after a recovery period of 3hrs at 37 °C. Analysed mRNA levels 
were normalized with RplP0 mRNA levels and expressed as relative levels mean of 4 independent replicates 
(*p < 0.05 vs DMSO; **p < 0.01 vs DMSO).
Figure 7. Colchicine and doxorubicin effects on the autophagic pathway (A–F) Q-PCR analyses of TFEB 
(A,B), p62/SQSTM1 (C,D) and LC3 (E,F) mRNA levels performed on SH-SY5Y cells treated as described 
in Fig. 6. The histograms represent analysed mRNA relative levels mean of 4 independent replicates (colchicine 
treatment, A, C and E; doxorubicin treatment, B, D and F) (*p < 0.05 vs DMSO; **p < 0.01 vs DMSO).
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compounds on the total amount of GFP-TDP-43 and GFP-TDP-25 insoluble species in FRA. Very interestingly, 
the treatment with colchicine resulted in a great reduction of insoluble species generated both by GFP-TDP-43 
and by GFP-TDP-25 (Fig. 9D), while doxorubicin was particularly active on the GFP-TDP-25 fragment (Fig. 9D). 
We estimated the percentage of reduction in the accumulation of the two TDP-43 variants and found that the 
intensity of the effects exerted by the two compounds on the full length or on the fragment of TDP-43 were much 
more intense in the case of colchicine than in the case of doxorubicin (Fig. 9E).
Discussion
In NDs characterized by the formation of inclusions containing misfolded proteins, the toxicity associated with 
these proteins can be counteracted by the activation of the PQC system. We previously characterized a specific 
member of the chaperone family, HSPB8, which is highly expressed in affected muscles of tg ALS mice and 
knock-in SBMA male mice models9,19,22. HSPB8 is also highly expressed in the spinal cord motor neurons of tg 
ALS mice that survive to mutant SOD1 toxicity at end stage of disease13,14 and in spinal cord of ALS patients20. 
HSPB8 has a potent pro-degradative activity for the elongated ARpolyQ involved in SBMA11,12,17,45, as well as for 
the mutant SOD1 and a C-terminal truncated fragment of TDP-43 responsible for different forms of fALS. The 
importance of HSPB8 is underlined also by its prodegradative activity on other misfolded proteins, such as htt in 
HD, ataxin-3 in SCA-3 and beta-amyloid in AD10,39.
Here, we demonstrated that HSPB8 also prevents the accumulation of misfolded species generated by TDP-43 
and, especially, its 25 KDa fragment (TDP-25, involved in most sALS and FLTD forms). These species are known 
to exert their toxicity by mislocalizing TDP-43 from nucleus to cytoplasm54, where they aggregate entrapping 
rightly folded TDP-43, thereby reducing its nuclear functions47,55,56. The pro-degradative activity of HSPB8 has 
been associated with its capability to facilitate and enhance the autophagic removal of misfolded species by acting 
in conjunction with the HSP70/HSC70 co-chaperone BAG3 and CHIP13,14,18, as well as to counteract autophagic 
flux blockage induced by misfolded mutant proteins9,12. Therefore, with the aim to test the effects of HSPB8 
Figure 8. Colchicine and doxorubicin effects on HSPB8 expression are TFEB-independent (A–F) 
Analysis of the TFEB silencing on HSPB8 expression performed on SH-SY5Y cells transfected with an 
ON-TARGETplus TFEB siRNA or scramble siRNA, and treated with 500 nM of colchicine or doxorubicin, 
and with DMSO for 24 hrs. (A) Q-PCR analyses of TFEB mRNA levels. TFEB mRNA relative levels were 
normalized on the levels of RplP0 and expressed as mean of 4 independent replicates (**p < 0.01 vs scramble/
DMSO; °°p < 0.01 vs siRNA-TFEB/DMSO, #p < 0.05 and ##p < 0.01 vs treatment-corresponding scramble 
samples). (B) The histogram represents the quantification of the TFEB silencing (expressed as percentage). 
(C) Q-PCR analyses of HSPB8 mRNA levels (**p < 0.01 vs scramble/DMSO; °°p < 0.01 vs siRNA-TFEB/
DMSO). (D) WB and WB quantification of TFEB (E) and HSPB8 (F) protein levels. The histograms represent 
densitometric analysis of three independent replicates for each sample (*p < 0.05 and **p < 0.01 vs scramble/
DMSO; °p < 0.05 and °°p < 0.01 vs siRNA-TFEB/DMSO, ##p < 0.01 vs treatment-corresponding scramble 
samples).
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Figure 9. Colchicine and doxorubicin effects on TDP-43 and TDP-25 aggregation (A) Representative 
immunofluorescence microscopy analysis (63x magnification and 2.5x zoom) performed in SH-SY5Y cells 
transiently transfected for 24 hrs with GFP-TDP-43 or GFP-TDP-25 plasmids and then treated for 24 hrs 
with 1 μM colchicine, doxorubicin or DMSO. Left panels: GFP-TDP-43; right panels: GFP-TDP-25. DAPI: 
nuclei staining. RED: HSPB8. (B) Quantification of GFP-TDP-43 and GFP-TDP-25 positive cells with GFP-
spots using Operetta Imaging System and Harmony software analysis (Perkin Elmer) on living SH-SY5Y cells 
transiently transfected and treated as described in A. Spots are defined with a range of size from 1 to 10 μm2 
in SH-SY5Y treated as in A. SD refers to four independent replicates in HCS. (*p < 0.05 and **p < 0.01 vs 
untreated control). (C) Quantification of spots area in GFP-TDP-43 and GFP-TDP-25 positive SH-SY5Y cells 
after drugs treatment obtained by Harmony software analysis (Perkin Elmer).(n = 4). (*p < 0.05 and **p < 0.01 
vs untreated control). (D,E) Representative FRA and FRA quantifications of the PBS extracts of SH-SY5Y cells 
transiently overexpressing the GFP-TDP-43 or GFP-TDP-25 plasmids treated or not with 500 nM of colchicine 
(left insets) or doxorubicin (right insets) the day after transfection, for the last 24 hrs prior to extraction. (D) 
The histograms represent densitometric analysis of three independent replicates for each sample (**p < 0.01 vs 
untreated GFP-TDP-43; °p < 0.05 vs untreated GFP-TDP-25). (E) The histogram represents the quantification 
of the GFP-TDPs insoluble species reduction percentage after treatment with colchicine or doxorubicin.
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induction for therapeutic purposes, in this study we set up a novel motoneuronal cell system to perform a HTS of 
small molecules to identify inducers of HSPB8 expression.
Our cell system is based on the stable expression of the luciferase cDNA driven by the human HSPB8 gene 
promoter in immortalized motor neurons12,13. We found several compounds that were able to activate the HSPB8 
promoter as evaluated by the induction of luciferase activity in the transcriptional reporter assay. Combining 
their activities with their safety, we selected few candidates that were further tested for their power to enhance the 
expression of the endogenous HSPB8 in neuronal cells.
Some compounds able to induce HSPB8 transcription are estrogenic drugs57. However, neuronal SH-SY5Y 
cells do not express the two isoforms of estrogen receptor (ERalpha and ERbeta) and are thus unresponsive to 
these drugs. This represents an obvious limitation for the potential use of estrogenic compounds to enhance 
HSPB8 expression for therapeutic purposes, since their activity, in the specific neuronal population affected in 
ALS or FLTD, strictly depend on the brain distribution of the ERs, which may jeopardize the protective effects of 
the drugs. Additionally, we observed that 14% out of compounds has not obvious annotation of biological activ-
ity, as the case of derrubone (our first hit) of which some recent reports have highlighted a molecular chaperone 
activity58,59, further supporting the validity of our approach.
In the secondary screening on SH-SY5Y, we identified two compounds that robustly up-regulated, and in a 
dose-dependent manner, the expression of the human HSPB8: colchicine and doxorubicin. These compounds did 
not modify the expression of HSF1, a master regulator of the stress response, and a direct target of HSF1, BAG360. 
Colchicine did not induce the expression of BAG1 while doxorubicin exerted a positive effect61, supporting the 
idea that doxorubicin may also activate a proteasomal response51. Conversely, both colchicine and doxorubicin 
positively regulated the expression of TFEB, the master regulator of the autophagic process, and of p62/SQSTM1 
and LC3 that are specifically required to sustain the autophagic flux. Finally, both drugs counteracted the accu-
mulation of both TDP-43 and TDP-25 misfolded species responsible for motoneuronal death in sALS.
It is interesting to note that both colchicine and doxorubicin are approved by FDA for the treatment of human 
diseases; but their safety and side effects are very different. Doxorubicin is a chemotherapic agent used in differ-
ent cancer type (e.g. blood cancers, solid tumors and in sarcomas)62. The mechanism of action of doxorubicin 
is based on its property to intercalate and bind to DNA, inhibiting its replication by blocking the topoisomerase 
II and triggering apoptosis63,64. Additionally, it can activate an autophagic response that facilitates cell survival65. 
Doxorubicin needs to be administered intravenously and, unfortunately, when used chronically, is characterized 
by severe side effects, the most relevant being linked to heart damages, leading to cardiomyopathy62,66. Indeed the 
prolonged, doxorubicin-induced, autophagic and proteasomal response has been addressed as a co-cause of car-
diomyocyte death67; however, increased acute autophagy with co-administration of rapamycin and doxorubicin 
rescued doxorubicin toxicity68.
Conversely, colchicine is a safer drug as compared to doxorubicin. Colchicine acts mainly by inhibiting 
microtubule polymerization during mitosis as a spindle poison69,70; with this activity colchicine blocks neutrophil 
motility and activity, and it is characterized by an anti-inflammatory activity. Because of that, colchicine is com-
monly used in gout treatment71,72, and less frequently, in pericarditis and recurrence of atrial fibrillation after car-
diac tissue ablation73,74. Colchicine is administered orally, and it is usually well tolerated at low doses and shows 
limited adverse effects at high doses particularly on the gastrointestinal tract73. A potential limitation of colchicine 
has been observed in some patients with advanced renal failure exposed to long-term (prophylactic) oral colchi-
cine treatment, in which a low fraction of colchicine is not metabolized and not removed by hemodialysis, caus-
ing cumulative toxicity that resulted in neuromyopathy75–77. Interestingly, high doses of colchicine combined with 
starvation enhance the autophagy flux in skeletal muscle of normal mice78. Surprisingly, the same approach, used 
to induce autophagy in tgALS mice, correlated with a reduced autophagic flux, possibly because of the presence of 
an excess of the misfolded SOD1 in skeletal muscle of these mice78. The study correlated the reduced autophagic 
flux with the fact that in skeletal muscle expressing mutant SOD1 there is an increased activity of caspase-3, which 
targets several key proteins involved in autophagy, such as Beclin-1, an important protein that bridges autophagy 
with apoptosis78. Thus, an altered autophagy activity can be at the basis of mutant SOD1 (and of other misfolded 
proteins) toxicity in this tissue9,19,21,22. Unfortunately, no treatments with colchicine alone were tested to clarify if 
this effect has to be ascribed to the effect of starvation or the combined factors. Obviously, as a proof of principle, 
the analysis of colchicine effect (and possibly doxorubicin) in animal models (both wt and tg models of NDs) will 
also confirm whether the drug is able to induce HSPB8 expression in skeletal muscle and in neurons (including 
motoneurons) affected by proteotoxicity of misfolded proteins. These studies will also clarify whether colchicine 
(or doxorubicin) ameliorates clinical signs of disease and whether it is capable to extend survival of affected mice. 
This will allow to design analogs of the two HSPB8 inducers characterized by better safety and tolerability profiles.
Methods
Chemicals. Dimethyl sulfoxide (DMSO), Colchicine, Doxorubicin and MG132 were obtained from Sigma-
Aldrich (St. Louis, MO, USA), 3-Methyladenine (3-MA) was obtained from Selleckchem (Munich, Germany), 
Geneticin (G418) was from Euroclone (Pero, Milan, Italy). The commercial library of 2,000 compounds was from 
MicroSource (SPECTRUM Collection, MicroSource, USA).
Plasmids. GFP-hPromB8LUC codes for the GFP protein under the control of the CMV promoter, and the 
firefly luciferase under the control of the human HSPB8 gene promoter. This plasmid was obtained by excising 
the promB8LUC sequence from the promB8 plasmid13 using KpnI-HpaI sites and, after blunting ends, cloning it 
into the AflII cutting-site of the pEGFP-N1 vector (Clontech Lab; Mountain View, CA, USA). pRL-TK was from 
Promega (Madison, WI, USA). pcDNA3 was obtained from Life Technologies Corporation (Carlsbad, CA, USA). 
The pEGFP-TDP-43 and pEGFP-TDP-25 code for the GFP-fused TDP-43 full-length protein (GFP-TDP-43) and 
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its C-terminal 25 KDa (GFP-TDP-25) fragment, respectively, and were kindly provided from Dr. Petrucelli79. 
pCI-HSPB8 plasmid codes for human HSPB845.
Cell culture, transfection and treatments. NSC34 immortalized mouse motoneuronal cell line80,81 is 
routinely cultured and maintained in our lab82–85. NSC34 cells were plated at (i) 3.5*104 cells/well in 24-well 
multiwell plate with coverslips for immunofluorescence analysis; (ii) 4*104 cells/well in 24-well multiwell plate 
for transcriptional activity assay; (iii) 8*104 cells/well in 12-well multiwell plate for Western Blot (WB) and Filter 
Retardation Assay (FRA) analyses. 24 hrs after plating, cells were transiently transfected with Lipofectamine (Life 
Technologies Corporation; Carlsbad, CA, USA)/transferrin (Sigma-Aldrich), following Manufacture’s instruc-
tions, as described in13.
Stably transfected NSC34-GFP-hPromB8LUC cells were obtained as described in86, by transiently transfecting 
NSC34 cells with the GFP-hPromB8LUC plasmid and selecting positive clones (#Ns) with G418 (400 μg/ml) for 3 
weeks. Selected clones were cultured in high-gluocose DMEM supplemented with 5% FBS (Sigma-Aldrich) and 
G418 (100 μg/ml), and were plated at 4*104 cells/well in 24-well multiwell plates, for transcriptional activity assay.
SH-SY5Y human neuroblastoma cell line was cultured in DMEM/F12 supplemented with 10% FBS 
(Sigma-Aldrich), Pen/Strep (5 U/mL of penicillin and 5 μg/mL of streptomycin), glutamine (2.5 mM). SH-SY5Y 
cells were plated at (i) 2*105 cells/well in 12-well multiwell plate for Q-PCR, WB and FRA analyses; (ii) 1.5*104 
cells/well in 24-well multiwell plate with coverslips for immunofluorescence analysis. Cells were transiently trans-
fected 24 hrs after plating with Lipofectamine 2000 (Life Technologies), using i) GFP-TDP-43 or GFP-TDP-25 
plasmids (1 μg) and Lipofectamine (4 μl; amounts for 1 well of a 12-well multiwell); ii) ON-TARGETplus TFEB 
siRNA or scramble siRNA (40 pmol) (Dharmacon, Thermo Scientific Life Sciences Research, Waltham, MA, 
USA) and Lipofectamine (2 μl; amounts for 1 well of a 12-well multiwell), following manufacturer’s instructions. 
Where indicated, cells were treated with different compounds for the last 24 hrs prior to extraction. For heat shock 
experiment, cells were plated at 2*105 cells/well in 12-well multiwell and, 48 hrs after plating, cells were grown for 
1 hr at 42 °C and extracted or allowed to recover for 3 hrs at 37 °C prior to extraction.
Microscopy and Immunofluorescence. NSC34 (3.5*104 cells/well) or SH-SY5Y (7.5*104 cells/well) 
cells plated in 24-well multiwell plates were transfected with GFP-TDP-43 or GFP-TDP-25 plasmids (0.5 μg) 
and treated as indicated for 24 hrs prior to extraction. 48 hrs after transfection NSC34 transfected cells were 
fixed and processed as previously described85. The following antibodies were used: (a) rabbit polyclonal anti-P62/
SQSTM1 (ab91526, Abcam, Cambridge, MA, USA; dilution 1:500 in 5% nonfat milk) to detect endogenous p62/
SQSTM1 protein expression; (b) rabbit polyclonal anti-LC3 (L8918, Sigma-Aldrich; dilution 1:500 in 5% nonfat 
milk) to detect endogenous LC3 protein expression; (c) home-made rabbit polyclonal anti-hHSPB8 (#25, dilution 
1:200 in 5% nonfat milk) to detect hHSPB8. Alexa 594 anti-rabbit secondary antibody was used (A11072, Life 
Technologies; dilution 1:1,000 in 5% nonfat milk). DAPI or Hoechst33342 were used to stain nuclei. An Axiovert 
200 microscope (Zeiss Instruments, Oberkochen, Germany), equipped with FITC/TRITC/DAPI filters and com-
bined with a Photometric Cool-Snap CCD camera (Roper Scientific, Trenton, NJ, USA) was used to acquire 
images (resolution: 63X). The Metamorph software (Universal Imaging, Downingtown, PA, USA) was used for 
images processing.
Filter Retardation and Western Blot assays, Preparation of Protein Extracts and Antibodies. 
NSC34 cells plated at 8*104 cells/well in 12-well multiwell plates were transfected with GFP-TDP-43 or 
GFP-TDP-25 plasmids (0.5 μg) and pCDNA3 or hHSPB8 plasmids (0.6 μg). SH-SY5Y were plated and transfected 
as described above. NSC34 and SH-SY5Y transfected cells were harvested 48 hrs after transfection and centri-
fuged 5 min at 100 g at 4 °C. The pellets were resuspended in PBS added with protease inhibitor and homogenized 
using slight sonication as previously described85,86. Total protein level was determined with the bicinchoninic acid 
method (BCA assay).
For FRA, protein extracts (1.5 μg, for NSC34 transfected cells; 9 μg for SH-SY5Y transfected cells) were loaded 
on 0.2 μm cellulose acetate membrane (Amersham, GE Healthcare Buckinghamshire, UK) and filtered through a 
Bio-Dot SF Microfiltration Apparatus (Bio-Rad Laboratories, Hercules, CA, USA).
WB analysis was performed on 12% SDS polyacrylamide gel loading 15 μg of proteins for NSC34 cells and 
30 μg of proteins for SH-SY5Y cells. Samples were electro-transferred to nitrocellulose membranes (Bio-Rad) 
using TransBlot Turbo Apparatus (Bio-Rad). Nitrocellulose and acetate membranes were processed as previ-
ously described85,86. The following primary antibodies were used: (a) rabbit polyclonal anti-GFP HRP conjugate 
to detect GFP-TDP-43 and GFP-TDP-25 species (MB-0712; Vector Laboratories, Burlingame, CA, USA; dilu-
tion 1:5,000); (b) home-made rabbit polyclonal anti-HSPB8 (#25; dilution 1:1,000) to detect HSPB8; (c) mouse 
monoclonal anti-α -tubulin (T6199, Sigma-Aldrich; dilution 1:4,000) to detect tubulin; (d) rabbit polyclonal 
anti-GAPDH to detect GAPDH (sc25778; Santa Cruz Biotechnology; dilution 1:1000); (e) rabbit polyclonal 
anti-TFEB to detect TFEB (A303-673A; Bethyl Laboratories, Montgomery, TX, USA; dilution 1:2,500). The sec-
ondary peroxidase-conjugated antibodies were: goat anti-rabbit (sc-2004; Santa Cruz Biotechnology; dilution 
1:20,000); goat anti-mouse (sc-2005, Santa Cruz Biotechnology; dilution 1:20,000). Signals were detected using 
Clarity™ Western ECL Blotting Substrate (Bio-Rad). 20 min room temperature stripping reaction (StripABlot, 
EuroClone) allowed subsequently processing of nitrocellulose membranes with different antibodies.
Transcriptional activity assay. NSC34 cells plated at 4*104 cells/well in 24-well multiwell plates were 
transfected with GFP-hPromB8LUC plasmid (0.25 μg) and pRL-TK plasmid (0.25 μg; used for inducible fire-
fly luciferase activities normalization). Selected clones of stably transfected NSC34-GFP-hPromB8LUC cells 
(#N1 - #N10) were plated at 4*104 cells/well in 24-well multiwell plates and allowed to growth for 48 hrs. Where 
indicated, cells were treated with MG132 (10 μM) for the last 16 hrs prior to transcriptional activity assay. 
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Transcriptional activity was measured using the LucLite Kit (Perkin Elmer, Waltham, MA, USA) and the Dual 
Luciferase Assay System (Promega), according to the manufacturer’s protocols, as previously described in13 sup-
plementary data. Six independent replicates were analysed for each conditions tested.
High Throughput Screening (HTS) assay and hits validation. The #N4 clone of stably trans-
fected NSC34-GFP-hPromB8LUC cells has been selected and used to carry out the HTS experiments. The 
primary screening campaign, performed in duplicate, has been conducted using the SPECTRUM Collection 
(MicroSource, USA) library of compounds, containing 60% of clinically used drugs, 25% of natural products and 
15% of other bioactive small molecules. All dispensation steps were performed by the 96 channels pipetting head 
of a TECAN EVO 200 (TECAN) and compounds were added at the final concentration of 1 μM. HTS assay has 
been optimized by seeding 4*104 cells/well in View-96-well plates (PerkinElmer), by treating them with MG132 
(5 μM), used as transcriptional activator of HSPB813 and technical positive control in the assay. 24 hrs later, the 
GFP signal was detected using the Operetta HTS imaging system (PerkinElmer) at 10x magnification with 3 
fields of view/well, and subsequently the relative luminescence units were quantified with an Infinite M200 plate 
reader (TECAN) after dispensing 1:1 ONE-Glow substrate (Promega) and incubation for 30 min at room tem-
perature in the dark. Images were analyzed with Columbus 2.1 (PerkinElmer) and the ratio between the lumi-
nescence units and GFP mean fluorescence intensity of the cells has been considered the read-out of the assay. 
Z-factor and CV, and Z-score values, calculated as already described87 were the parameters for assay quality and 
compounds ranking, respectively. Counter-screening experiments have been performed using a range of 3 doses 
(0.1, 1, and 10 μM) of selected compounds and by measuring the viability of #N4 cells with Alamar blue assay 
(Life Technology). Statistical significance was calculated by means of 2-way ANOVA and Bonferroni post-test 
compared with DMSO values for each drug dose. Imaging of SH-SY5Y transiently transfected with GFP-TDP-43 
plasmids has been performed with Operetta instrument (Perkin Elmer) with a 20x objective; analysis of number 
and size (range from 1 to 10 μm2) of spots in GFP-positive cell population was carried out with Harmony software 
(Perkin Elmer).
RNA extraction and Q-PCR analysis. SH-SY5Y cells were plated at 2*104 cells/well in 12-well multiwell 
plate, allowed to growth for 24 hrs, and then treated for 24 hrs with a range of 3 doses of different compounds 
(100 nM, 500 nM, or 1 μM; as indicated), or with DMSO (negative control) or MG132 (10 μM; positive control). 
Treated cells were harvested and centrifuged 5 min at 100 × g at 4 °C; the pellets were resuspended in 300 μL 
of TRI Reagent (Sigma-Aldrich); total RNA was isolated according to manufacturer’s instructions, quantified 
and reverse transcribed into cDNA as previously described11, using the High-Capacity cDNA Archive Kit (Life 
Technologies) according to the manufacturer’s protocol. All primers for Q-PCR were designed using the program 
Primer 3 and synthesized by MWG Biotech (Ebersberg, Germany) with the following sequence: hBAG1: 5′ -TTT 
AGA GCA GCC CGA GTG AT-3′ (forward), 5′ - GAC AGC AGA CAG CCA ACA AA-3′ (reverse); hBAG3: 5′ - 
GGG TGG AGG CAA AAC ACT AA-3′ (forward), 5′ -AGA CAG TGC ACA ACC ACA GC-3′ (reverse); hHSF1: 
5′ - CAT GAA GCA TGA GAA TGA GGC T-3′ (forward), 5′ -ACT GCA CCA GTG AGA TCA GGA-3′ (reverse); 
hHSPB8: 5′ - AGA GGA GTT GAT GGT GAA GAC C-3′ (forward), 5′ -CTG CAG GAA GCT GGA TTT TC-3′ 
(reverse); hMAP-LC3b: 5′ -CAG CAT CCA ACC CAA AAT CCC (forward), 5′ -GTT GAC ATG GTC AGG 
TAC AAG-3′ (reverse); hRplP0: 5′ -GTG GGA GCA GAC AAT GTG GG-3′ (forward), 5′ -TGC GCA TCA TGG 
TGT TCT TG-3′ (reverse); hp62/SQSTM1: 5′ -CCA GAG AGT TCC AGC ACA GA-3′ (forward), 5′ -CCG ACT 
CCA TCT GTT CCT CA-3′ (reverse); hTFEB: 5′ -GCT GAT CCC CAA GGC CAA T-3′ (forward), 5′ -TCT CCA 
GCT CCC TGG ACT TT-3′ (reverse). Q-PCR was performed using the iTaq SYBR Green Supermix (Bio-Rad), 
in a 10 μl total volume, with 500 nM primers. CFX 96 Real-Time System (Bio-Rad) was used with the following 
cycling conditions: 94 °C for 10 min, 40 cycles at 94 °C for 15 s and 60 °C for 1 min. Data were analysed and 
expressed as previously described11,22. Values were normalized to those of RplP0. All statistics were performed 
with ∆ Ct values. Each experiment was carried out with four independent samples.
Statistical analysis. Statistical analysis has been performed using Student’s t-test or 2-way ANOVA using 
the PRISM software (GraphPad Software, La Jolla, CA, USA).
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